1-(2,2-Dimethyl-1-phenyl-propyl)-piperidine | 132637-69-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2,2-Dimethyl-1-phenyl-propyl)-piperidine
• 英文别名: 1-(2,2-Dimethyl-1-phenylpropyl)piperidine
• CAS: 132637-69-5
• 化学式: C₁₆H₂₅N
• 分子量: 231.381
• InChiKey: PEFNKGZSHCHSET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  叔丁基锂 、 N-(phenylselenocarbonyl) piperidine 以 四氢呋喃 为溶剂， 以75%的产率得到1-(2,2-Dimethyl-1-phenyl-propyl)-piperidine
  参考文献：
  名称：

  硒酰胺与有机锂试剂反应的一种新型脱硒反应

  摘要：

  硒酰胺与有机锂试剂的反应以亲碳化方式进行，更有趣的是，过量锂试剂的存在会导致碳亲化加合物发生新的脱硒反应。

  DOI：

  10.1246/cl.1990.2053

文献信息

• Mixed Aliphatic Organozinc Reagents as Nonstabilized C_sp³-Nucleophiles in the Multicomponent Mannich Reaction
  作者：Marine Pinaud、Erwan Le Gall、Marc Presset

  DOI：10.1021/acs.joc.1c02996

  日期：2022.4.1

  use of mixed aliphatic organozinc reagents in the multicomponent Mannich reaction is described. A large variety of primary, secondary, and tertiary organozinc reagents, secondary amines and aromatic or aliphatic aldehydes could be used for the straightforward preparation of densely substituted amines. The three-component reaction could additionally be performed starting from alkyl halides under reductive

  描述了在多组分曼尼希反应中使用混合脂肪族有机锌试剂。大量的伯、仲和叔有机锌试剂、仲胺和芳族或脂族醛可用于直接制备密集取代的胺。三组分反应还可以在还原（巴比尔型）条件下从卤代烷开始进行。
• SEKIGUCHI, MASAHITO;OGAWA, AKIYA;FUJIWARA, SHIN-ICHI;RYU, ILHYONG;KAMBE, +, CHEM. LETT.,(1990) N1, C. 2053-2056
  作者：SEKIGUCHI, MASAHITO、OGAWA, AKIYA、FUJIWARA, SHIN-ICHI、RYU, ILHYONG、KAMBE, +

  DOI：——

  日期：——
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20120076756A1

  公开（公告）日：2012-03-29

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US8673954B2
  申请人：——

  公开号：US8673954B2

  公开（公告）日：2014-03-18